CALR and essential thrombocythemia: About 90% of ET cases represent a molecular clonal marker: JAK2 p.V617F (50–60%), MPL p.W515L/K (3–15%) mutations, and CALR 52 bp deletion or 5 bp insertion (20–25%) [10,11,12].